DEFECTS IN THE PRECORE REGION OF THE HBV GENOME IN PATIENTS WITH CHRONIC HEPATITIS-B AFTER SUSTAINED SEROCONVERSION FROM HBEAG TO ANTI-HBE INDUCED SPONTANEOUSLY OR WITH INTERFERON THERAPY

被引:85
作者
TAKEDA, K
AKAHANE, Y
SUZUKI, H
OKAMOTO, H
TSUDA, F
MIYAKAWA, Y
MAYUMI, M
机构
[1] JICHI MED SCH,DIV IMMUNOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN
[2] YAMANASHI MED COLL,DEPT INTERNAL MED 1,YAMANASHI 40938,JAPAN
[3] KITASATO INST,IMMUNOL SECT,TOKYO 108,JAPAN
[4] MITA INST,TOKYO 108,JAPAN
关键词
D O I
10.1002/hep.1840120606
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hepatitis B virus DNA clones were propagated from sera of six patients with chronic hepatitis B who seroconverted from HBeAg to antibody to HBeAg either spontaneously or after administration of alpha-interferon. Defects in the precore region blocking synthesis and secretion of HBeAg were detected in all 46 hepatitis B virus DNA clones from three patients who remained positive for antibody to HBeAg and in whom hepatitis resolved. Defective clones had point mutations from guanine to adenine at nucleotide 83 in the precore region, converting codon 28 from tryptophan (TGG) to a stop codon (TAG). In contrast, this defect was not found in any of 39 hepatitis B virus DNA clones from three patients who seroconverted to antibody to HBeAg but then redeveloped HBeAg with reactivation of hepatitis. Using these results, the G-to-A point mutation at nucleotide 83 in the precore region would predict sustained positivity for antibody to HBeAg and remission of hepatitis in patients who have seroconverted either spontaneously or with interferon therapy.
引用
收藏
页码:1284 / 1289
页数:6
相关论文
共 29 条
[1]   CHRONIC ACTIVE HEPATITIS WITH HEPATITIS-B VIRUS-DNA AND ANTIBODY AGAINST E-ANTIGEN IN THE SERUM - DISTURBED SYNTHESIS AND SECRETION OF E-ANTIGEN FROM HEPATOCYTES DUE TO A POINT MUTATION IN THE PRECORE REGION [J].
AKAHANE, Y ;
YAMANAKA, T ;
SUZUKI, H ;
SUGAI, Y ;
TSUDA, F ;
YOTSUMOTO, S ;
OMI, S ;
OKAMOTO, H ;
MIYAKAWA, Y ;
MAYUMI, M .
GASTROENTEROLOGY, 1990, 99 (04) :1113-1119
[2]  
ALEXANDER GJM, 1987, LANCET, V2, P66
[3]   WHICH PATIENTS WITH CHRONIC HEPATITIS-B VIRUS-INFECTION WILL RESPOND TO ALPHA-INTERFERON THERAPY - A STATISTICAL-ANALYSIS OF PREDICTIVE FACTORS [J].
BROOK, MG ;
KARAYIANNIS, P ;
THOMAS, HC .
HEPATOLOGY, 1989, 10 (05) :761-763
[4]  
BRUNETTO MR, 1989, ITAL J GASTROENTEROL, V21, P151
[5]   FORMATION OF TRANSMEMBRANEOUS HEPATITIS-B E-ANTIGEN BY COTRANSLATIONAL INVITRO PROCESSING OF THE VIRAL PRECORE PROTEIN [J].
BRUSS, V ;
GERLICH, WH .
VIROLOGY, 1988, 163 (02) :268-275
[6]  
CARMAN WF, 1989, LANCET, V2, P588
[7]  
DAVIS GL, 1984, GASTROENTEROLOGY, V86, P230
[8]  
Dienstag JL, 1984, VIRAL HEPATITIS LIVE, P135
[9]   PILOT-STUDY OF RECOMBINANT HUMAN ALPHA-INTERFERON FOR CHRONIC TYPE-B HEPATITIS [J].
DOOLEY, JS ;
DAVIS, GL ;
PETERS, M ;
WAGGONER, JG ;
GOODMAN, Z ;
HOOFNAGLE, JH .
GASTROENTEROLOGY, 1986, 90 (01) :150-157
[10]   RECOMBINANT LEUKOCYTE INTERFERON TREATMENT OF CHRONIC HEPATITIS-B [J].
DUSHEIKO, G ;
DIBISCEGLIE, A ;
BOWYER, S ;
SACHS, E ;
RITCHIE, M ;
SCHOUB, B ;
KEW, M .
HEPATOLOGY, 1985, 5 (04) :556-560